PRO 302
Alternative Names: miR-302; PRO-302Latest Information Update: 03 Nov 2022
At a glance
- Originator Prolifagen Therapeutics
- Class Cardiovascular therapies; MicroRNAs
- Mechanism of Action Hippo signaling pathway modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Heart failure